SCHEMBL25940606

SCHEMBL25940606

CC(=O)Cn1nc(I)c2ccc(C(=O)OCc3ccccc3)cc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.48
▸ TDP1 Q9NUW8 4/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ ALDH1A1 P00352 5/20 0.46
▸ RAB9A P51151 5/20 0.46
▸ LMNA P02545 4/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ NPC1 O15118 3/20 0.46
▸ JMJD6 Q6NYC1 1/20 0.44
▸ KMT2A Q03164 3/20 0.44
▸ SLC6A2 P23975 1/20 0.44
▸ SLC6A3 Q01959 1/20 0.44
▸ HPGD P15428 1/20 0.43
▸ HTT P42858 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.40
▸ SRD5A1 P18405 1/20 0.40
▸ SRD5A2 P31213 1/20 0.40
▸ CNR2 P34972 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ MAT2A P31153 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25940602 0.87 TDP1 (0.48) MAPTTDP1L3MBTL1ALDH1A1RAB9A
SCHEMBL20487896 0.87 MAPT (0.42) MAPTTDP1L3MBTL1ALDH1A1RAB9A
SCHEMBL25925436 0.83 GAA (0.40) MAPTALDH1A1RAB9ALMNASMN1; SMN2
SCHEMBL12480283 0.83 MAPT (0.48) MAPTTDP1L3MBTL1ALDH1A1RAB9A
SCHEMBL29854924 0.78 MAPT (0.43) MAPTTDP1L3MBTL1ALDH1A1RAB9A
SCHEMBL20488622 0.78 MAPT (0.43) MAPTTDP1L3MBTL1ALDH1A1RAB9A
SCHEMBL20489035 0.76 TDP1 (0.44) MAPTTDP1L3MBTL1ALDH1A1RAB9A
SCHEMBL12480120 0.75 LMNA (0.43) MAPTTDP1L3MBTL1ALDH1A1RAB9A
SCHEMBL25925420 0.73 MAPT (0.43) MAPTALDH1A1RAB9ALMNAHPGD
SCHEMBL22349631 0.73 TDP1 (0.54) MAPTTDP1L3MBTL1ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11718626-B2 Macrocyclic compounds for treatment of medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2023-08-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718626-B2 Macrocyclic compounds for treatment of medical disorders CFD, TFPI, CFH MAPT 3729/4885TDP1 4701/4885L3MBTL1 4664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback